Citius Pharmaceuticals Inc. (CTXR) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization

Graphic logo of Citius Pharma (CTXR)

Citius Pharmaceuticals is diversifying its operations by developing treatments for oncology and critical care. This chart illustrates the current share value with an EV/EBITDA ratio of 0.00. This price action reflects the potential for premium pricing following the approval of its lymphoma therapy, while ultimate success depends on the commercialization of Mino-Lok and the completion of final trials for its intensive care drugs.

CTXR Citius Pharmaceuticals, Inc.: Enterprise Value to Operating Income Before Depreciation in the range 11/23/2025 - 11/11/2026

CTXR (citiuspharma.com): analytical breakdowns and indicator data

- stock price and consensus target price:
Stock Quotes Citius Pharmaceuticals, Inc.|CTXR - Fair Value Consensus
- market capitalization indicators:
Market Value Citius Pharmaceuticals, Inc.|CTXR - Total Enterprise Value
- book value of equity indicators:
Net Assets per Single Share Citius Pharmaceuticals|CTXR - Accounting Capitalization|Market Capitalization to Book Value Ratio citiuspharma.com|CTXR - Cumulative Company Assets
- debt and liquidity data:
Debt to Equity Citius Pharmaceuticals|CTXR - Long-Term Liabilities to Capital|Short-Term Debt to Equity Citius Pharmaceuticals, Inc.|CTXR - Company Debts|Debt to Book Capitalization Ratio Citius Pharmaceuticals, Inc.|CTXR - Long-Term Debt|Company Short-Term Debts Citius Pharmaceuticals|Quick Liquidity Indicator citiuspharma.com
- business earnings and investment ratios data:
CTXR - Company Net Income|Future Profit Citius Pharmaceuticals|CTXR - Company Value to Net Income|Projected Price to Earnings Citius Pharmaceuticals, Inc.|CTXR - Company Value to Earnings Growth Ratio|EV/EBITDA Multiple Citius Pharmaceuticals, Inc.|CTXR - Income before deduction of interest, taxes and amortization|Net earnings per share (EPS TTM) Citius Pharmaceuticals|CTXR - Net earnings per one share for the last twelve months|Year-over-year earnings per share growth for the last twelve months citiuspharma.com|CTXR - Earnings per share increase in current year|Earnings growth forecast for next year Citius Pharmaceuticals
Summary company analytics:CTXR (Citius Pharma)
Original product of Citius Pharmaceuticals, Inc.

By utilizing a virtual operating model that outsources all testing to third-party contractors, Citius Pharmaceuticals (CTXR) minimizes capital expenditures, which directly impacts the calculation of enterprise value relative to its operating profit. Analyzing the EV/EBITDA valuation multiple for capital-intensive businesses, an investor determines the payback period for assets excluding taxes and interest, where the stability of the curve may signal either reliability or stagnation.

Competitor analysis

Incyte Corp. - Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation HCM|NUVB - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to EBITDA dayonebio.com|Monopar Therapeutics Inc. (MNPR) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to Operating Income Before Depreciation INBX|IMAB (I-Mab Biopharma Co., Ltd.) - EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio Fennec (FENC)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Heron Therapeutics (HRTX)|NVCT - Company Value to EBITDA|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Coherus BioSciences Inc. CHRS|Corbus Pharmaceuticals Holdings, Inc. - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|CRDF - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to EBITDA BeyondSpring Inc|BCAB: EV/EBITDA Multiple|Enterprise Value to EBITDA Multiple lixte.com LIXT|Enterprise Value to EBITDA Ratio CLRB|Company Value to EBITDA BioLineRx Ltd BLRX|Enterprise Value to EBITDA Ratio CANF (Can-Fite BioPharma, Ltd.)|APRE (aprea.com) - Business Value to Operating Income Before Depreciation|Kazia Therapeutics Limited - Enterprise Value to EBITDA Ratio|Enterprise Value to Operating Income Before Depreciation Ratio SLXN (Silexion Therapeutics Corp.)|NuCana Corp - EV/EBITDA Multiple|Business Value to Operating Income Before Depreciation CMRX (Chimerix Inc.)|CYCC: EV/EBITDA Multiple|Company Value to EBITDA G1 Therapeutics (GTHX)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Kronos Bio, Inc.|KTRA: Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple ONCT|EV/EBITDA Multiple Portage Biotech Inc (PRTG)